bioRxivCancer BiologyPreprint
BAZ1A, an Imitation Switch (ISWI) protein, interacts and facilitates the recruitment of E2F1 to activate the E2F transcription program
Bidisha Prajapati, Abhishek ChowdhuryiD, Kaval Reddy Prasasvi, Lakshay Garg, Kumaravel SomasundaramiD
Abstract
ISWI (Imitation Switch) family of chromatin remodeling complexes mobilize nucleosomes to regulate DNA-template associated functions. Analysis of glioblastoma (GBM) transcriptome datasets revealed that BAZ1A (Bromodomain Adjacent to Zinc Finger Domain 1A) is a highly expressed ISWI family member. RNAi-based depletion or inhibition by a small molecule inhibited the survival/migration of glioma cells and glioma stem-like cells (GSCs), sensitized glioma cells to Temozolomide but did not affect normal astrocytes. BAZ1A-silencing arrested cells in the G1 phase and induced apoptosis. While GO analysis of BAZ1A regulated transcriptome showed enrichment of "cell cycle" related terms, GSEA showed a depletion of the "HALLMARK_E2F_TARGETS" gene set with the highest significance, indicating a nonfunctional E2F transcription program. BAZ1A silencing and overexpression experiments confirmed the requirement of BAZ1A for the E2F transcription program by identifying E2F1 as the primary target. ChIP experiments revealed that BAZ1A and E2F1 bind to the E2F1 promoter. ChIP-ReChIP demonstrated that BAZ1A-bound chromatin fragments are enriched for E2F1 protein on the E2F1 promoter at specific sites. SMARCA1/5, ATPase subunits of the ISWI family, also exhibited binding to the E2F1 promoter. BAZ1A depletion decreased the DNaseI sensitivity of E2F1 binding regions of the E2F1 promoter. Co-immunoprecipitation experiments revealed an interaction between BAZ1A and E2F1 and the presence of an E2F1-BAZ1A-SMARCA1/5 complex. Finally, BAZ1A silencing inhibited glioma tumor growth in an orthotopic xenograft mouse model. Our results demonstrate that BAZ1A containing ISWI complex recruits E2F1 to activate the E2F transcription program, thus promoting G1-S progression and highlighting BAZ1A as a potential therapeutic target.
- organism: human
- assay: bulk RNA-seq
- research focus: chromatin & epigenetic regulation
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Pathway-based approach reveals differential sensitivity of glioblastoma to E2F1 inhibition
A. G. Alvarado, K. Tessema, … H. I. Kornblum·bioRxiv·Jun 19, 2021
- Suppression of YAP/TAZ molecular targets by epigenetic editing interferes with GBM growth and invasiveness
Eva Baronchelli, Silvia Ferretti, … Alessandro Sessa·bioRxiv·Mar 15, 2026
- SOX21 Suppresses Glioblastoma Growth by Repressing AP-1 Activity
Eltjona Rrapaj, Juan Yuan, … Jonas Muhr·Cell Death and DiseasePeer-reviewed·Jan 31, 2026
- ASCL1 regulates neurodevelopmental transcription factors and cell cycle genes in glioblastoma
T. Y. Vue, R. Kollipara, … J. E. Johnson·bioRxiv·Feb 20, 2020
- Hijacking the transcriptional activation potential of the BAF complex via Induced Proximity
L. Chia, D. Mayhew, … A. M. Taherbhoy·bioRxiv·Dec 18, 2023
- EZH2 inhibition in glioblastoma stem cells increases the expression of neuronal genes and the neuronal developmental regulators ZIC2, ZNF423 and MAFB
B. Kader, R. DiStefano, … A. G. West·bioRxiv·Nov 22, 2021